International workshop on immune tolerance induction: consensus recommendations 1 by Dimichele, D. M. et al.
International workshop on immune tolerance induction:
consensus recommendations1
D. M. DIMICHELE,* W. K. HOOTS, S. W. PIPE, G. E. RIVARD§ and E. SANTAGOSTINO–
*Department of Pediatrics, Weill Medical College of Cornell University, New York, NY; Department of Pediatrics,
University of Texas Medical School, Houston, TX; Department of Pediatrics, University of Michigan, Ann Arbor, MI,
USA; §Department of Pediatrics, University of Montreal, QC, Canada; and –A. Bianchi Bonomi Hemophilia and
Thrombosis Center, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, University of Milan, Milan,
Italy
Summary. Although immune tolerance induction
(ITI) has been used for 30 years to eliminate
inhibitors and restore normal factor pharmacoki-
netics in patients with hemophilia, there is a paucity
of scientific evidence to guide therapeutic decision-
making. In an effort to provide direction for
physicians and hemophilia treatment center staff
members, an international panel of hemophilia
opinion leaders met to develop consensus recom-
mendations for ITI in patients with severe and mild
hemophilia A and hemophilia B. These recommenda-
tions draw on the available published literature and
the collective clinical experience of the group and are
rated based on the level of supporting evidence .
Keywords: factor VIII, factor IX, hemophilia A,
hemophilia B, immune tolerance induction, inhibi-
tors
Introduction
The development of inhibitors that neutralize the
function of factor VIII (FVIII) or factor IX (FIX) is
the most serious complication associated with the
treatment of haemophilia. Inhibitors occur in up to
30% of patients with severe haemophilia A (FVIII
<1% of normal) [1–3], 0.9–7% of patients with mild
to moderate haemophilia A [4] and 3% of patients
with haemophilia B [3]. The presence of an inhibitor
does not increase mortality, but it complicates
treatment and increases disease-related morbidity
because bleeding episodes do not respond to stand-
ard therapy [5]. While large doses of factor can
usually overcome low-titre inhibitors (£5 Bethesda
units (BU) [1]), high-titre inhibitors generally render
factor replacement ineffective, and bypassing ther-
apy is required [6]. Two bypassing agents are
currently available: the activated prothrombin com-
plex concentrate (aPCC), FEIBA (Baxter AG,
Vienna, Austria), and recombinant-activated FVII
(rFVIIa; NovoSeven, Novo Nordisk, Bagsvaerd,
Denmark). Both products have been shown to
control at least 80% of bleeding episodes associated
with high-titre inhibitors, including perioperative
bleeding [7–13]. However, their haemostatic efficacy
is difficult to predict [6,14] and does not reach the
overall success rates obtained with specific factor
replacement in patients without inhibitors [6,15].
Furthermore, no laboratory assays are available that
correlate with dosing or efficacy or predict compli-
cations [6]. Consequently, inhibitor patients, partic-
ularly those with high-titre, high-responding
inhibitors, are at increased risk for uncontrollable
haemorrhage, devastating joint disease and subse-
quent disability [16].
To reduce these risks and improve quality of life,
immune tolerance induction (ITI) is usually attemp-
ted to eliminate high-responding (anamnestic) FVIII
inhibitors of recent onset and restore normal factor
pharmacokinetics [14]. ITI may also be performed,
albeit far less frequently, in patients with high-titre
FIX inhibitors. The Bonn protocol, first described in
1977 [17], is the prototype from which subsequent
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ITI regimens evolved. All regimens utilize ongoing,
frequent, uninterrupted exposure to FVIII or FIX
over a period of a few months to two or more years
[18] with the goal of inducing antigen-specific
tolerance [14,19]. Despite three decades of clinical
experience with this modality, there is a lack of
scientific evidence to direct ITI decision-making.
Supporting data primarily come from small institu-
tional studies and the three major ITI registries
(International [20], German [21] and North Ameri-
can [22]). With regard to registry data, it was
retrospectively collected several years ago, and the
registries differed in terms of demographics; collec-
tion methods; and, in some instances, endpoints. The
International Immune Tolerance Induction (I-ITI)
Study [23], the first prospective, randomized, con-
trolled trial of immune tolerance, was launched in
July 2002 and currently involves 96 centres in 25
countries. This study is expected to resolve some of
these unanswered questions, but the final results may
not be known for several years, as subject accrual is
ongoing.
To provide haemophilia caregivers with interim
guidance, an international panel of haemophilia
opinion leaders gathered in New York, NY, on 9–
11 June 2006, and again in London, England, on 14–
16 September 2006, to accomplish two goals: First,
to critically evaluate the quality of the published
literature on the clinical use of ITI, associated
outcomes, and outcome-predictive variables in pa-
tients with inhibitors to FVIII or FIX. Secondly, to
formulate consensus on a set of recommendations for
ITI that draw on both the available published
literature and the collective clinical experience of
the group. These recommendations have been devel-
oped into decision-tree algorithms that physicians
and haemophilia treatment centre (HTC) staff mem-
bers may utilize and individualize according to the
unique needs of each patient. The background,
rationale and support for the algorithms are des-
cribed in detail. Each practice recommendation has
been assigned a rating based on the level of available
supporting evidence (Table 1) [24]. In addition to
these algorithms, the panel developed a list of
research priorities. This investigational call-to-action
is presented at the end of the supplement.
We are grateful for the opportunity to be guest
editors of this supplement to Haemophilia and to
work with our colleagues from Europe and North
America to develop the recommendations for ITI.
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Table 1. Levels of evidence [24].
Level Evidence
Ia Meta-analysis of randomized controlled trials (RCT)
Ib At least one RCT
IIa At least one well-designed, controlled study without
randomization
IIb At least one other type of well-designed,
quasi-experimental study
III Well-designed, non-experimental, descriptive studies
(e.g. comparative studies, correlational studies,
and case–control studies)
IV Expert committee reports or opinions and/or clinical
evidence offered by respected authorities
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Immune tolerance induction in patients with
severe haemophilia A
Overview of inhibitor formation
Studies in previously untreated patients (PUPs)
with severe haemophilia A suggest that most FVIII
inhibitors develop early in life (median age,
1.7–3.3 years), with the highest risk during the first
50 exposure days to factor concentrate [25,26].
Although genetic markers indicating a predisposition
to inhibitor development are not fully identified,
several other host factors are known to influence
the risk of inhibitor development. In addition to the
type and severity of haemophilia, these include FVIII
gene mutations, primarily large defects in multiple
domains [27]; polymorphisms in genes involved in
the regulation of the immune system [28–30], which
suggest that inhibitor formation is a polygenic
process; family history, linked to approximately a
threefold increased risk of inhibitor development
[31]; and African heritage, which doubles the risk
[32]. In addition, differences in the major histocom-
patibility complex, a critical component of the
immune system, may contribute to inhibitor devel-
opment [33]. The likelihood of inhibitor formation
may also be increased by environmental factors, such
as age at first factor exposure [34], intensive FVIII
exposure during infancy [35], immunologic chal-
lenge (e.g. infection, surgery, immunization) [36], or
choice of FVIII replacement concentrate (i.e. recom-
binant or plasma-derived) [37], but their roles in the
aetiologic process remain less certain. The entire ITI
algorithm for patients with severe haemophilia A is
presented in Fig. 1. The following sections discuss
the various components of this algorithm.
When to Start ITI
In 1999, Kroner [38] published a meta-analysis of
the data from the International Immune Tolerance
Registry (IITR) and the North American Immune
Tolerance Registry (NAITR). Collectively, these data
included information on 437 patients with haemo-
philia A and B evaluated for ITI. Among the putative
predictors of ITI success, only two were found to be
statistically significant in this meta-analysis: histor-
ical peak inhibitor titre and titre at the initiation of
ITI. ITI was successful in 82% of patients whose
peak titres were <50 BU, and as the historical titre
increased, success rates diminished (Table 2). This
inverse correlation between historical peak titre and
successful tolerance was also observed in the German
ITI registry [21].
While the maximum historical inhibitor titre may
influence decisions about whether to attempt ITI, the
pre-ITI titre is relevant to decisions about when to start
immune tolerance. An inhibitor titre of <10 BU
immediately before ITI initiation positively affected
both the likelihood of success and the time required to
achieve tolerance in the IITR and NAITR (Table 3)
[22], the German registry [21], the Spanish registry
[39] and in several institutional studies [40–44]. There
is some suggestion that waiting until the inhibitor titre
falls below 5 BU may further improve response [22],
but this has yet to be firmly established. Thus,
reasonable evidence supports the recommendation
that ITI should generally be deferred until the inhibitor
titre has dropped below 10 BU, although this may not
be the absolute cutoff. This postponement typically
delays the start of ITI by 3–6 months. According to an
early progress report from the I-ITI study, the median
delay between inhibitor development and a drop in the
inhibitor titre below 10 BU has been 6 months [23].
Despite waiting for the inhibitor titre to fall, the
median age of the children at the start of ITI was only
25 months. Close surveillance of inhibitory antibody
levels during the waiting period is essential to ensure
the prompt initiation of immune tolerance once the
titre falls sufficiently or alternative action if it does not.
During this interval, exposure to FVIII should be
avoided or minimized by discontinuing FVIII prophy-
laxis (if applicable) and treating intercurrent bleeding
on-demand with bypassing therapy [18]. rFVIIa is the
preferred agent for acute haemorrhage management in
this setting [18] since FEIBA, which contains residual
FVIII antigen, may cause anamnesis [26].
When bleeding is life- or limb-threatening or
has the potential to cause significant morbidity
Table 2. IITR and NAITR data meta-analysis: outcome by
maximum historical titre [38].
Maximum historical titre (BU)
Total<50 50–200 201–500 >500
IITR n (%)
Success 64 (82) 24 (65) 9 (56) 17 (50) 114
Failure 14 (18) 13 (35) 7 (44) 17 (50) 51
Total (P ¼ 0.004) 78 37 16 34 165
NAITR n (%)
Success 71 (82) 18 (69) 4 (40) 1 (7) 94
Failure 16 (18) 8 (31) 6 (60) 13 (93) 43
Total (P ¼ 0.001) 87 26 10 14 137
Reprinted with permission (pending) from Kroner BL. Compar-
ison of the international immune tolerance registry and the North
American immune tolerance registry. Vox Sang. 1999; 77(Suppl.
1):33–37.
IITR, International Immune Tolerance Registry; NAITR, North
American Immune Tolerance Registry.
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Fig. 1. Severe haemophilia A: recommended ITI algorithm.
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(e.g. haemarthrosis with risk of target joint develop-
ment), it may be prudent to start ITI prior to the
desired decline in titre to <10 BU. A significant
association between outcome and time from inhibitor
diagnosis to ITI was observed in the IITR, although
this association was only of borderline significance in
the NAITR [38]. Nonetheless, success rates for both
registries were at their lowest after 5 years (51% for
the IITR, 57% for the NAITR). Consequently, if the
waiting period for the inhibitor to decline extends
beyond 1–2 years, the advantages and disadvantages
of beginning ITI at a titre higher than 10 BU should be
considered.
Consensus recommendations for when to start
ITI (Fig. 1)
1 Postpone the initiation of ITI until the inhibitor titre
has dropped to <10 BU, although an even lower
inhibitor titre may be more beneficial (level IIb).
a. The waiting time is usually short, and most
children will still be very young at the start of
ITI.
b. Closely monitor inhibitory antibody levels
during the waiting period to ensure that ITI is
started promptly once the titre falls sufficiently.
c. Avoid FVIII exposureduring the waitingperiod.
2 Consider starting ITI regardless of the inhibitor
titre if (level IV)
a. The inhibitor titre does not fall below 10 BU
within a 1–2 year period of close observation.
b. A severe life- or limb-threatening bleeding
event occurs.
Fig. 1. Continued.
Table 3. IITR and NAITR data meta-analysis: outcome by Pre-ITI
titre [38].
Pre-ITI titre (BU)
Total<10 10–20 21–50 >50
IITR n (%)
Success 65 (79) 16 (76) 5 (36) 15 (53) 101
Failure 17 (21) 5 (24) 9 (64) 13 (46) 44
Total (P ¼ 0.002) 82 21 14 28 145
NAITR n (%)
Success 73 (87) 9 (50) 5 (38) 6 (33) 93
Failure 11 (13) 9 (50) 8 (62) 12 (67) 40
Total (P ¼ 0.001) 84 18 13 18 133
IITR, International Immune Tolerance Registry; NAITR, North
American Immune Tolerance Registry.
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FVIII dose
Dosing regimens
Three primary therapeutic regimens have been
developed for inhibitor eradication (Table 4). The
high-dose Bonn protocol currently calls for the
administration of FVIII at a dosage of 150 IU kg)1
twice daily [41]. FEIBA (50 U kg)1 b.i.d.) is added
in patients at high risk of bleeding and is continued
until the inhibitor titre falls below 1 BU. The Bonn
protocol is intensive for patients and families and
very costly because of high-FVIII consumption.
In the low-dose van Creveld (Dutch) regimen,
FVIII is administered every other day at a dose of
25 IU kg)1 [45]. The dose is decreased each time
the absolute FVIII recovery exceeds 30%. These
reductions are continued until a prophylactic FVIII
dose of 10–15 IU kg)1 three times weekly is
reached.
The Malmö protocol utilizes extracorporeal
immunoadsorption with protein A columns as nee-
ded to remove high-titre inhibitory antibodies
(>10 BU) [40,46]. This process is followed by
immunomodulation using intravenous and oral
cyclophosphamide and intravenous immune globulin
(IVIG) combined with high-dose FVIII (Bonn regi-
men). Hospitalization is required, but tolerization
has been reported in as little as 3–4 weeks. The
Malmö protocol is no longer used in Sweden for ITI
because the long-term follow-up showed that re-
sponses were not always durable [40,46,47], and that
success rates were no higher than for regimens that
do not use immunomodulation [40]. Furthermore,
immunoadsorption may be difficult in small children
[18], and the use of cyclophosphamide is potentially
associated with an increased risk of myelosuppres-
sion, leukemia and sterility [48]. These side effects of
cyclophosphamide are thought to be dose-related,
however, and may not occur at the doses used in the
Malmö protocol. In addition to these ITI regimens,
various intermediate-dose protocols have been devel-
oped at and are used by individual HTCs worldwide
[42,44,49].
Dosing considerations
Controversy persists regarding the roles of FVIII dose
and dosing regimen as predictors of ITI success [19].
While many investigators have reported similar rates
of successful tolerization (63–91%) despite the use of
widely disparate therapeutic dosing regimens
[40,42,44,49–51], the registries generated varied
data in this regard [20,38,52–54]. In the IITR, daily
FVIII doses of at least 200 IU kg)1 resulted in a
statistically significant improvement in outcome
(86%; P ¼ 0.001) [55]. In contrast, the NAITR
observed a significant inverse relationship between
FVIII dose intensity and overall ITI success. Success
rates were 80% for daily doses of <50 IU kg)1,
compared with 41% for doses of 200 IU kg)1 day)1
or higher (P ¼ 0.01) [54]. Tolerization was achieved
more rapidly, however, when higher doses were used
(‡50 IU kg)1 day)1) [53,54].
A meta-analysis of the two registries found that
FVIII dosing had no impact on ITI success rates for
good-risk patients with historical inhibitor titres
below 200 BU and pre-ITI titres of <10 BU [38].
There are strong proponents of the exclusive use of
high-dose ITI because of longstanding institutional
experience [51]. However, consideration of the
comparative cost-effectiveness and reduced morbid-
ity associated with lower-dose, non-daily regimens
[56] may be crucial to the broader availability of ITI
in both the developed and developing world. To this
end, the ongoing I-ITI study is evaluating the effect of
FVIII dose on the overall ITI success rate and time to
success by randomizing 150 good-risk, severe hae-
mophilia A subjects to receive FVIII doses of either
200 IU kg)1 daily or 50 IU kg)1 three times weekly
Table 4. Primary therapeutic regimens used for ITI.
Bonn protocol (high-dose regimen) [41]
FVIII 150 IU kg)1 b.i.d.
FEIBA 50 U kg)1 b.i.d. for patients at high risk of bleeding
Comments
Intensive for patients and families
Very costly due to high FVIII consumption
van Creveld (Dutch) Protocol (low-dose regimen) [45]
FVIII 25 IU kg)1 q.o.d.
Decrease dose each time absolute FVIII recovery is >30%
Continue until a prophylactic dose (10–15 IU kg)1 q.o.d.) is
reached
Comments
Less demanding for patients and families than the Bonn
regimen
More economical
Malmö Protocol (immunomodulation plus high-dose FVIII) [40]
Immunoadsorption followed by





May allow quick completion of ITI, resulting in cost savings
No longer used
Other Protocols
Gruppo: 50–100 IU kg)1 week)1 plus IM [49]
Rocino: 100 IU kg)1 day)1 [44]
Smith: 100 IU kg)1 b.i.d., then 100 IU kg)1 day)1 [42]
b.i.d., twice daily; IVIG, intravenous immune globulin; IM,
immunomodulation; q.o.d., every other day.
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for up to 33 months [23]. The need for reliable,
unbiased data is crucial, and it is recommended that
all ITI patients be enrolled either in a prospective,
randomized clinical trial or an international registry
[57,58].
In contrast to good-risk patients, dose may be
important for poor-risk patients, defined as those
with a peak historical inhibitor titre >200 BU and/or
a pre-ITI titre higher than 10 BU and/or time since
inhibitor diagnosis exceeding 5 years. According to
the meta-analysis of the IITR and NAITR data, only
high-dose regimens (‡200 IU kg)1 day)1) offer the
most reasonable chance of ITI success for individuals
with poor prognostic parameters [38]. Only one of
23 (4%) poor-risk patients treated with daily doses
of <200 IU kg)1 were successfully tolerized, whereas
higher doses effectively eradicated inhibitors in 12 of
18 patients (67%). ITI-naive patients with poor
prognoses will be eligible to participate in the Rescue
Immunotolerance (RESIST) Study, a companion trial
to the I-ITI study, that is scheduled to start in the
near future and will randomize patients to receive
high-dose ITI (200 IU kg)1 day)1) with either
recombinant FVIII (rFVIII) or a plasma-derived von
Willebrand factor (VWF)-containing FVIII concen-
trate [19]. Enrollment of poor-risk patients in pros-
pective, comparative clinical trials and a trial of dose
maximization among those who fail low-dose ITI is
strongly recommended.
Consensus recommendations for ITI dosing (Fig. 1)
1 Among good-risk patients (i.e. peak historical
titre <200 BU, pre-ITI titre <10 BU, <5 years
since diagnosis), no dosing regimen has been
shown to be superior to another. These patients
may be eligible to participate in the I-ITI study
(level IIb).
2 Among poor-risk patients (i.e. peak historical titre
>200 BU and a pre-ITI titre >10 BU and/or
>5 years since inhibitor diagnosis), the evidence
suggests a higher success rate with the use of high-
dose regimens (‡200 IU day)1). These patients
may be eligible to participate in the RESIST Study
(level IIb).
FVIII product
The choice of FVIII product to achieve inhibitor
eradication is another matter of debate. High ITI
success rates (73–91%) have been reported for
patients treated with monoclonal (plasma-derived
human FVIII produced using immunoaffinity chro-
matography and a monoclonal antibody to FVIII)
and recombinant FVIII concentrates [42,44,59–62],
yet some data suggest that plasma-derived FVIII
(pdFVIII) concentrates rich in VWF increase the
likelihood of successful tolerization.
A longitudinal study conducted at the HTC in
Frankfurt, Germany, showed that success rates using
a high-dose ITI protocol had declined from 91%
(19/21 patients) to 37.5% (six of 16 patients) with
the introduction of high-purity concentrates [63,64].
However, when patients who had an unsatisfactory
response to ITI using monoclonal or recombinant
FVIII were switched to concentrates containing high
amounts of VWF, eight of 10 (80%) experienced
complete eradication of their inhibitors. Similarly, a
compilation of data on ITI therapy from HTCs in
Bonn and Bremen, Germany, showed that before
1990, ITI was successful in 44 of 51 patients (86%)
treated exclusively with intermediate-purity FVIII/
VWF concentrates [65]. Success rates dropped to
55% between 1990 and mid-1999, when high-
purity FVIII products without VWF were primarily
used. With the resumed use of FVIII/VWF concen-
trates in July 1999, success rates increased to 71%.
Specifically, 23 of 28 patients (82%) undergoing ITI
with FVIII/VWF were successfully tolerized, com-
pared with six of 14 patients (43%) treated with
rFVIII.
Other researchers have also observed the enhanced
efficacy of VWF-containing concentrates in achiev-
ing tolerization. Orsini et al. [66] reported that ITI
was successful in eight of eight patients undergoing
ITI with a high-purity FVIII/VWF product. In
addition, prospective surveillance conducted by
Gringeri showed that six of 13 patients at high risk
for a poor response to ITI, including three patients
who had previously failed ITI, were successfully
tolerized using a high-purity FVIII/VWF concentrate
[67]. The remaining seven patients, who were still
undergoing ITI, converted from high- to low-
responder status.
One explanation for these favourable findings is
that VWF, in addition to being a critical component
of haemostasis [68] and playing key roles in FVIII
function, production and stabilization [68,69], may
also modulate FVIII immunogenicity [70], thereby
influencing ITI outcome. Inhibitors react with and
bind to active sites on the FVIII molecule, primarily
with epitopes in the A2, A3, C1 and C2 domains [71]
VWF binds to similar epitopes on the FVIII molecule
as inhibitors directed against the C2 domain, which
may result in epitope masking [72,73]. Conse-
quently, a small subset of FVIII antibodies may be
less inhibitory to FVIII complexed with VWF com-
pared with monoclonal and recombinant FVIII
products [74–77].
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The potentially beneficial effects of VWF notwith-
standing, immune tolerance is a multifactorial pro-
cess, and variables other than VWF contribute to
differences in success rates [73]. Moreover, it is
unclear if a switch from monoclonal or recombinant
FVIII to VWF-containing concentrates was respon-
sible for successful tolerization or if inhibitor erad-
ication simply resulted from an extended duration of
ITI. In other words, the patients may have become
immune tolerant had their original treatment regi-
mens been continued longer. Meta-analysis of data
from the IITR and NAITR found no association
between outcome and treatment product [38]. In the
IITR, 96% of patients were treated with intermedi-
ate-purity products; in the NAITR, monoclonal and
recombinant products were predominantly used. Yet
the distribution of success and failure was equivalent:
70% success, 30% failure. Furthermore, no pros-
pective, randomized trial has compared VWF/FVIII
with monoclonal or recombinant concentrates. Thus,
at the present time, there is no definitive evidence
demonstrating the superiority of any FVIII product,
although the RESIST trial may provide this data in
the future. Most patients are tolerized using the
product they were receiving when they developed an
inhibitor [15]. This approach is effective, and
switching to another FVIII product for de novo ITI
is not recommended.
Consensus recommendations for FVIII product (Fig. 1)
1 ITI is successful using FVIII products with and
without VWF (level IIb).
2 No data support the superiority of any FVIII
product (level IIb).
3 Most patients are tolerized with the same FVIII
product in use at the time of inhibitor detection.
This approach works, and there is no evidence to
support switching to another FVIII product for
de novo ITI (level IIb).
Immunoadsorption
Extracorporeal immunoadsorption, a component of
the Malmö ITI protocol when necessary [40] involves
selectively removing immunoglobulins and immune
complexes using Staphylococcal protein A or anti-
immunoglobulin columns [78]. The process, which
eliminates approximately 70–90% of circulating
inhibitory antibodies [79], appears to be more useful
for patients with acquired haemophilia than for those
with severe congenital haemophilia with inhibitors
[80]. Accordingly, there is no role for immuno-
adsorption as a first-line component of ITI.
Consensus recommendations for immunoadsorption
(Fig. 1)
1 There is no role for immunoadsorption as a first-
line component of ITI (level IIb).
Prophylaxis during ITI
The results of the randomized controlled US Joint
Outcome Study, reported by Manco-Johnson in
2005, established the efficacy of FVIII prophylaxis
in preventing joint damage in patients with severe
haemophilia A without inhibitors [81]. Other inves-
tigators have shown that FVIII prophylaxis indirectly
improves academic performance [82] and quality of
life [83]. Increasingly, prophylaxis with bypassing
therapy is being used for patients with FVIII inhib-
itors, as they are at increased risk for joint disease
and severe haemorrhage [16] owing to the difficulty
in controlling bleeding episodes [84].
FEIBA has been a component of the Bonn ITI
regimen for 30 years [17], and it is currently used in
patients at high risk for bleeding [51] Kreuz et al.
[85] prospectively evaluated FEIBA prophylaxis in
22 children, aged 0.1–6 years, with high-titre inhib-
itors (>5 BU) undergoing ITI. FEIBA was adminis-
tered at a dose of 50 U kg)1 daily, with the dosage
increased up to 100 U kg)1 twice daily for break-
through bleeding. The median annual incidence of
joint bleeding during FEIBA prophylaxis was one
(range, 0–6), and no patient suffered a life-threaten-
ing haemorrhage. No evidence of arthropathy was
seen in six of eight patients evaluated radiographi-
cally; and in the remaining two patients, joint
pathology was minimal. Valentino prospectively
studied three inhibitor patients, aged 3.7–24.1 years,
who received concomitant FEIBA prophylaxis at a
daily dose of 100 U kg)1 during ITI [86]. The
incidence of joint bleeding prior to the initiation of
prophylactic therapy ranged from 2.5 to 4.08 per
100 days and declined to 0.0–1.42 per 100 days
during treatment, a reduction of 65–100%. FEIBA
was well tolerated and did not cause thrombosis.
Historically, rFVIIa is less likely to be used for
prophylaxis outside of the perioperative setting
because of its shorter half-life (approximately 3 h in
adults [87] and even more rapid clearance rates in
children [88]), compared with FEIBA (4–7 h) [89].
Although future clinical practice may change subse-
quent to the pilot data presented by Konkle et al. [90]
on the efficacy of rFVIIa in inhibitor patients not
concomitantly receiving ITI, a current review of the
literature identified only one case study describing the
successful use of rFVIIa prophylaxis during immune
8 D. M. DIMICHELE et al.
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tolerance. Saxon et al. [91] reported that rFVIIa at a
dose of 90 lg kg)1 once daily significantly reduced the
number of target joint bleeding episodes in a pre-
school-aged boy undergoing ITI. The efficacy of
rFVIIa in this patient may indicate that rFVIIa may
have a longer biologic effect than is indicated by its
half-life, according to the authors [91].
Potential drawbacks to the concurrent use of
bypassing agent prophylaxis during ITI include the
high cost and risk of thrombosis [92]. When bypas-
sing therapy is used outside the ITI setting, throm-
botic risk is very low. Whether the same holds true
when these products are used concurrently with ITI
is unknown.
By avoiding an inflammatory environment in
which the tolerogenic delivery of FVIII is not
possible, prophylaxis during immune tolerance may
prevent major haemorrhage, thereby shortening the
duration of ITI and improving the likelihood of
success. However, data supporting such a hypothesis
are limited. In patients undergoing immune tolerance
who experience early joint bleeding or intracranial
haemorrhage (ICH), prophylaxis with a bypassing
agent may be considered. The dose of FEIBA
recommended based on reports of bypassing-agent
prophylaxis during ITI [85,86,91] and outside the
ITI setting [93,94] is 50–200 U kg)1 every day to
twice weekly, and the recommended dose of rFVIIa is
90–270 lg kg)1 daily [90]. The higher ends of the
dosing ranges should be used for prophylaxis fol-
lowing ICH because of the significant risk of recur-
rent bleeding [95] FVIII recovery should be
monitored frequently once the inhibitor titre drops
to 10 BU or below (following anamnesis triggered by
ITI initiation). In an attempt to prevent the sporadic
development of catheter-associated vessel thrombosis
that has been reported with the concurrent use of ITI
and bypassing agents [96], it is the consensus opinion
that prophylaxis with bypassing agents should be
discontinued when any level of FVIII recovery is
detected.
When ITI is postponed to allow the inhibitor titre
to decline to <10 BU, FEIBA is not recommended for
the first-line prophylaxis because of its potential to
protract anamnesis [18]. The use of rFVIIa is
preferred in this setting at a recommended dose of
90–270 lg kg)1 daily.
Consensus recommendations for prophylaxis during ITI
(Fig. 1)
1 Prophylaxis should be considered if patients con-
tinue to bleed frequently while awaiting or on ITI
(level III).
2 rFVIIa at a dose of 90–270 lg kg)1 daily is pre-
ferred for prophylaxis when ITI is delayed to allow
the inhibitor titre to decline to <10 BU (level IV).
3 Prophylaxis with FEIBA (50–200 U kg)1 daily to
twice weekly) or rFVIIa (90–270 lg kg)1 day)1)
may be considered for patients undergoing ITI who
experience early joint bleeding or ICH (level III).
4 Monitor FVIII recovery when the inhibitor titre
drops to 10 BU (level IV).
5 Discontinue bypassing therapy at any level of FVIII
recovery (level IV).
Central venous access device issues
General recommendations
Uninterrupted and uncomplicated venous access is
essential in children undergoing ITI. Peripheral
venipuncture is the first choice [97], and some HTCs
initially attempt immune tolerance using regimens
that involve less frequent FVIII administration, as
this may facilitate peripheral venipuncture [18].
Nonetheless, central venous access devices (CVADs)
are often necessary for ITI in young children,
particularly for high-dose regimens [97].
Two major types of long-term CVADs are avail-
able: tunnelled and fully implantable (referred to as
ports) and tunnelled external catheters [98]. Among
haemophilia patients receiving long-term therapeutic
interventions, subcutaneously implanted single-res-
ervoir ports are the most commonly used CVADs
[99]. In patients without inhibitors, ports are pref-
erable to external devices [97] because they are less
likely to become infected by pathogens than are
external catheters [100]. The panel supports this
recommendation for inhibitor patients as well. Pub-
lished guidelines [97] for catheter care should be
meticulously followed by physicians and nurses.
Furthermore, because long-term CVAD use requires
considerable commitment from caregivers and pa-
tients, comprehensive education should be provided




Infection is the major complication associated with
CVADs used in haemophilia [99,101,102], and it is
the most common cause for their removal [98]
CVAD infection occurs more frequently in haemo-
philia patients with inhibitors [98,101,103], possibly
due to subcutaneous bleeding around the port that
facilitates entrance of Gram-positive bacteria
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through the skin, a situation unique to the pediatric
inhibitor population [104]. Infection rates are par-
ticularly high among inhibitor patients undergoing
ITI, ranging from 50% to 83%, according to a
review by van den Berg et al. [104]. Increased CVAD
access for daily FVIII administration may explain
this higher incidence [101]. The development of
catheter infections may cause interruptions in ITI
that prolong tolerization or lead to treatment failure
by provoking an anamnestic increase in the inhibitor
titre [15,18].
Preliminary data from the I-ITI study confirm that
CVAD infection occurs frequently during immune
tolerance [23,105]. Thirteen of 36 subjects (36%)
enrolled in the trial as of January 2006 had devel-
oped at least one catheter infection. Furthermore, ITI
success rates were observed to be lower, failure rates
higher, and response to treatment slower in these
individuals than in subjects without infection. Spe-
cifically, five subjects (38%) with infection achieved
a negative inhibitor titre after a median of 14 months
on ITI, compared with 17/22 uninfected patients
(77%) who achieved the same status after a median
of 7.5 months. Another five (38%) of the 13 subjects
with a history of CVAD infection have thus far met
the criteria for ITI failure. Published guidelines on
CVAD care [98] provide clinical strategies for the
prevention of catheter-related infection as well as
catheter management in the presence of a single or
recurrent infection.
Thrombosis
Thrombotic events associated with CVADs may
result in catheter occlusion or catheter-related
thrombosis [98], and the risk of such events increases
with the duration of catheter placement [106]. A
meta-analysis by Valentino et al. [98] of 48 studies
involving a total of 2704 patients and 2973 CVADs
found a pooled incidence of thrombosis of 0.056 per
1000 catheter days. The presence of an inhibitor did
not significantly affect thrombosis incidence, in
contrast to infection rate.
When a CVAD-related deep vein thrombosis (DVT)
is detected, the panel recommends discontinuing
bypassing prophylaxis (if used) and reviewing infusion
techniques with the family. Consideration should be
given to removing the catheter and transitioning to
peripheral venipuncture and also to modifying the ITI
regimen. Clot resolution may occur spontaneously
after catheter removal or even when the catheter is left
in place [98]. Patients should be monitored closely,
and if a severe clot fails to resolve or if it progresses,
catheter-directed thrombolysis or a short course of
anticoagulation should be considered.
Mechanical dysfunction
Mechanical problems may also occur with ports
[98], although this complication is less common than
infection or thrombosis [101]. Mechanical dysfunc-
tion may lead to catheter removal [101], and all such
events should be reported to the appropriate gov-
ernmental regulating agency.
Arteriovenous fistulae
An infectious or thrombotic complication may limit
the long-term use of a CVAD [107]. Arteriovenous
fistulae (AVF), considered the vascular access of
choice for haemodialysis patients because of their
durability and low complication rate [108], are a
protocol-driven option for venous access in children
aged 1 year and older who have experienced repea-
ted CVAD failure. Santagostino et al. [107] prospec-
tively studied the long-term safety and feasibility of
AVF in 27 children with severe haemophilia A,
including 14 with inhibitors. The AVF were regularly
and successfully used at home by 26 patients (96%)
for a median of 29 months. Venous thrombosis
occurred in one patient after 9 months, but symp-
toms spontaneously disappeared, and the AVF was
used for an additional 9 months.
Adapting AVF to the requirements of children
with haemophilia requires surgical expertise, and
long-term follow-up with ultrasonography and
echocardiography is necessary. All AVF should be
dismantled as soon as peripheral veins provide
adequate vascular access. Although ITI can continue
if an AVF-related thrombosis occurs, prophylactic
bypassing therapy should be stopped.
Consensus recommendations for CVAD issues (Fig. 1)
1 Use peripheral venous access whenever possible
(level IV).
2 Ports are preferable to external catheters because of
the significantly lower risk of infection (level IV).
3 Follow published guidelines for catheter care and
infection prevention (level IV).
4 Instruct families on CVAD techniques before
starting ITI (level IV).
5 If an infection develops, follow published guide-
lines on CVAD management (level IV).
6 If a CVAD-related DVT occurs, discontinue
bypassing prophylaxis (if used) and review infu-
sion techniques with family (level IV) in addition
to the following:
a. Consider removing the catheter and transi-
tioning to peripheral venipuncture (level IV).
b. Consider modifying the ITI regimen and fu-
ture bypass therapy regimens (level IV).
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7 Monitor closely for clot resolution (level IV).
8 If a severe clot fails to resolve or progresses, con-
sider (level IV)
a. Catheter-directed thrombolysis
b. A short course of anticoagulation
9 An AVF is a protocol-driven option for venous
access in children at least 1 year of age who have
experienced repeated CVAD failure (level IV).
a. Surgical expertise is essential in adapting
AVF to the requirements of children with
haemophilia (level IV)
b. Long-term follow-up of AVF with ultraso-
nography and echocardiography is necessary
(level IV)
c. Dismantle an AVF as soon as peripheral veins
provide adequate vascular access (level IV).
d. ITI can continue if an AVF-related throm-
bosis develops, but stop prophylactic
bypassing therapy (level IV).
Incomplete or lack of response to ITI
The time to ITI success is extremely variable, ranging
from a few months to two or more years [18]. In the
NAITR, while successful outcomes were achieved
more quickly in patients who received FVIII doses of
at least 50 IU kg)1 daily, the majority of patients
treated with lower doses were successfully tolerized,
albeit more slowly [26]. Thus, one strategy for
patients who demonstrate no response or an incom-
plete response to ITI is to give the current treatment
regimen additional time to produce results, partic-
ularly if a low-dose regimen is being used for reasons
of preferential or default use of peripheral access. In
the IITR, daily doses of at least 200 IU kg)1 were
associated with statistically significantly higher suc-
cess rates [55]. Although these data cannot be
extrapolated to second-line or salvage ITI strategies,
an alternative approach used in clinical practice is to
maximize the ITI dose.
A switch to an intermediate-purity VWF-contain-
ing FVIII product may be an option for patients
whose response to immune tolerance using mono-
clonal or recombinant FVIII is suboptimal. Given the
small repository of published evidence suggesting
that VWF-containing concentrates improve the like-
lihood of successful tolerization [64–67], coupled
with the predominant use of intermediate-purity
products in the IITR to achieve the reported outcome
with the first-line ITI [22], consideration may be
given to changing to a FVIII/VWF product.
The addition of rituximab to the ITI regimen may
improve response rates in patients who remain
difficult to tolerize [109,110]. Rituximab is a mono-
clonal antibody against CD20-positive B cells that
has shown promise in the treatment of acquired
haemophilia (autoantibodies) [111,112]. However,
published experience with this agent in the treatment
of alloantibodies associated with congenital haemo-
philia is limited to approximately two dozen patients
[109,113–123]. Among these patients treated with
rituximab at a dose of 375 mg m)2 given once
weekly for 4 weeks, 16 (73%) achieved an undetect-
able inhibitor based on the Bethesda assay. After
90 days–2 years of follow-up, 55% remained in
remission. Interpretation of these data is hampered
by the variable regimens used, some of which
included steroids, vincristine, or cyclosporine
[116,117], and the likelihood of preferential report-
ing of positive outcomes. Nonetheless, the 22
patients compose a group with poor prognostic
indicators, and a 55% response rate is encouraging.
Treatment of patients using a standardized protocol
and the reporting of consecutive patients is a
necessary first step to collecting interpretable data.
Consensus recommendations for managing incomplete
or lack of response to ITI (Fig. 1)
1 Continue the initial ITI regimen, particularly if a
low-dose regimen is being used for reasons of
preferential or default use of peripheral access
(level IV).
2 Maximize the ITI dose if a lower dose regimen is
being used and adequate venous access exists (level
IV).
3 Consider switching to a FVIII/VWF product if ITI
was initiated with a monoclonal or recombinant
product (level III).
4 Consider adding rituximab or another immune-




The pharmacokinetic parameters currently used to
define ITI success in patients with severe and mild
haemophilia A were established by consensus at the
Second International Conference on Immune Toler-
ance held in Bonn, Germany, in 1997. These
parameters include an undetectable inhibitor level
(<0.6 BU), FVIII plasma recovery ‡66% of pre-
dicted, FVIII half-life ‡6 h after a 72-h FVIII
washout period, and the absence of anamnesis upon
further FVIII exposure [57]. This definition has been
adopted by the I-ITI study [23], which defined partial
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success as a reduction of the inhibitor titre to <5 BU;
FVIII recovery of less than 66% of predicted; and
FVIII half-life of <6 h after a 72-h FVIII washout
period associated with clinical response to FVIII
therapy and no increase in the inhibitor titre
exceeding 5 BU over a 6-month period of on-demand
treatment or 12 months of prophylaxis [124].
Potential alternative definitions of ITI success based
on measurable parameters of immunologic tolerance
and/or the emerging biochemistry of FVIII clearance
were explored by the panel. However, none were
thought to be sufficiently definitive at this time to
supplant or complement the current definition.
Cost-effectiveness as a defining parameter of ITI success
ITI success may also be defined on the basis of its
cost-effectiveness. The majority of direct costs asso-
ciated with the care of haemophilia patients are
attributable to clotting factor replacement therapy
[125]. These costs are greater in patients with high-
titre inhibitors because they require bypassing ther-
apy, which is more expensive. Costs may further
increase as a result of the outlier effect caused by a
small percentage of inhibitor patients who require a
disproportionate amount of treatment.
An analysis of 314 patients enrolled in the IITR
found that 70% of patients with good prognostic
indicators (i.e. pre-ITI titre <10 BU, <5 years since
inhibitor diagnosis, high-dose ITI regimen)
achieved tolerance within 1 year, whereas those
with poor prognostic indicators required 2.5 years
of treatment to achieve comparable results [126].
The total cost of ITI in a patient with good
prognostic indicators was estimated to range from
US $900 000 to $1.8 million, depending on whe-
ther plasma-derived or recombinant product was
used. This cost increased to an estimated US
$6.3 million–12.6 million in a patient with poor
prognostic indicators.
Colowick et al. [127] modelled the cost-effective-
ness of ITI as a long-term strategy for inhibitor
management. Their Markov model showed that
while the cost of immune tolerance in a 5-year-old
child approached $1 million, successful ITI would
result in a lifetime reduction in the need for replace-
ment clotting factor (including bypassing therapy) of
$1.7 million. Moreover, successful tolerization in-
creased life expectancy by 4.6 years.
An alternative strategy to the Markov decision
model developed by Colowick is to compare ITI
intervention costs and outcomes, whether or not
successful, with those of patients with lifelong high-
titre inhibitors. Such a comparison would require
meticulously gathered cost and quality of life (QOL)
data from representative cohorts of inhibitor pa-
tients. Recently completed studies that have captured
some of this information [128–131] may make this
feasible in the future. Cost-effectiveness as a measure
of ITI success is also being examined by the I-ITI
study. At the current time, however, cost-effective-
ness parameters could not be incorporated into a
definition of ITI success.
Failure
Pharmacokinetic parameters
The pharmacokinetic definition of ITI failure
currently adopted by the I-ITI study was also
established by consensus at the Second International
Conference on Immune Tolerance. It is defined as
failure to achieve a full or partial success within
33 months or the failure to achieve an ongoing
reduction in the inhibitor titre of at least 20% during
each interim, non-overlapping, 6-month period after
the first 3 months of ITI (in the absence of docu-
mented infection) [124]. This definition implies that
9 months is the minimum treatment period and
33 months is the maximum reasonable duration of
unsuccessful ITI.
In clinical practice, ITI is sometimes continued
beyond 33 months, and a resistant minority of
patients may take 3 years or more to achieve
tolerance [132]. Clinical improvement, including
fewer bleeding episodes and improved QOL, may
favour continuing ITI [128]. However, economic
considerations often determine how long ITI is
pursued [20].
Potential alternative definitions of ITI failure based
on measurable parameters of immunologic tolerance
and/or the emerging biochemistry of FVIII clearance
were discussed. However, none were thought to be
sufficiently definitive at this time to supplant or
complement the current definition.
Consensus recommendations for defining ITI outcome
(Fig. 1)
1 Pharmacokinetic parameters of success: (level III)
a. A normal inhibitor titre
b. Normal FVIII recovery (‡66% of predicted)
c. Normal FVIII half-life (‡6 h) after a 72-h
FVIII washout period
d. Absence of anamnesis upon further FVIII
exposure
2 Pharmacokinetic parameters of partial success:
(level III)
a. An inhibitor titre <5 BU
b. FVIII recovery <66% of predicted
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c. FVIII half-life <6 h after a 72-h FVIII wash-
out period
d. Clinical response to FVIII
e. No increase in the inhibitor titre >5 BU over
a 6-month period of on-demand therapy or a
12-month period of prophylaxis
3 Pharmacokinetic parameters of failure: (level III)
a. Failure to fulfil criteria for full or partial
success within 33 months
b. Less than a 20% reduction in the inhibitor
titre for any 6-month period during ITI after
the first 3 months of treatment, which im-
plies that
i. 9 months is the minimum period for ITI;
ii. 33 months is the maximum duration of
ITI, although the decision may be made
to continue immune tolerance
Immune tolerance induction in patients with
mild haemophilia A
Compared with alloantibodies that develop in severe
FVIII deficiency, inhibitors associated with mild
FVIII deficiency tend to arise later in life, reflecting
the infrequency of bleeding episodes in this patient
population and the resultant decreased need for
treatment [133].
Inhibitors in mild haemophilia A are often
associated with a familial predisposition and the
presence of high-risk mutations that induce a
conformational change in the FVIII molecule
resulting in a functional FVIII defect [133]. In a
cohort of mild haemophilia A patients with inhib-
itors described by Hay et al. [134], 41% of treated
family members also had a history of FVIII
inhibitors. High-risk mutations in the FVIII gene
and intensive replacement therapy, such as for
surgery, trauma, or muscle bleeding, are other risk
factors for inhibitor development in mild haemo-
philia A. An inhibitor titre and baseline FVIII level
should be obtained for all patients with mild
haemophilia A and a family history of inhibitors
or when genotyping reveals the presence of high-
risk mutations. Screening should be repeated at
each clinic visit if the patient has received FVIII in
the interim and should be performed both preop-
eratively and postoperatively. When patients with
mild haemophilia A undergo surgery, FVIII replace-
ment therapy should be closely monitored, as it is
common for inhibitors to present with postopera-
tive haemostatic failure [133].
Bleeding manifestations associated with mild
haemophilia A and inhibitors are similar to those
observed with acquired antibodies (alloantibodies)
[135,136]. Patients may develop severe and per-
sistent bleeding, often in soft tissue and the
gastrointestinal and genitourinary tracts, that is
relatively or completely refractory to FVIII replace-
ment therapy and may be life-threatening [133].
Desmopressin acetate (DDAVP) and other therapies
that avoid FVIII exposure (e.g. bypassing agents)
should be used for the management of bleeding
episodes in patients with mild haemophilia A and
inhibitors in circumstances where the response to
testing is adequate. Both low-titre and high-titre
alloantibodies may disappear spontaneously but
may recur when the patient is re-exposed to FVIII
[133].
Inhibitors in patients with mild haemophilia A
also resemble autoantibodies in their poor response
to traditional ITI [136]. The Malmö regimen may
be more effective than other protocols in com-
pletely eradicating inhibitors associated with mild
haemophilia A, according to published reports, but
the number of patients reported on is too small to
reach any firm conclusions [133]. If immune
tolerance is being considered, it is advisable to
first rechallenge the patient with FVIII, keeping in
mind that a lack of anamnesis does not mean the
inhibitor will not return upon subsequent rechal-
lenge [133,135]. No recommendations can be made
for ITI, but if treatment is initiated, the data
should be reported to national and international
registries. A retrospective collection of data is
currently being performed in France and Belgium,
in an effort to increase knowledge and improve the
understanding of mild haemophilia A complicated
by an inhibitor [135]. Preliminary results from this
group of patients, who have a significantly lower
median age than that reported by Hay [133],
suggest a higher response rate to ITI [135].
Nonetheless, these success rates are still lower than
those reported for severe haemophilia A.
Consensus recommendations for ITI in patients
with mild haemophilia A (Fig. 2):
1 There can be no recommendations for ITI in mild
haemophilia A.
2 If ITI is initiated, report data to national and
international registries.
Immune tolerance induction in patients with
haemophilia B
Approximately 3% of patients with haemophilia B
develop inhibitors [3], and more than 80% of these
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alloantibodies are high-responding [137]. The devel-
opment of inhibitors in patients with haemophilia B
is generally associated with the absence of FIX
antigen caused by large or complete deletions or
major derangements of the FIX gene [138]. These
mutations are also linked to severe allergic anaphy-
lactoid or life-threatening anaphylactic reactions to
FIX concurrent with the appearance of an inhibitor
[139]. This is a well-recognized phenomenon that
occurs almost exclusively in conjunction with FIX
inhibitor development.
The aetiology of allergic reactions remains unclear.
The small molecular mass of the FIX protein
(55 000 kDa) accounts for its extracellular distribu-
tion, and this feature of FIX may contribute in some
way to hypersensitivity reactions in haemophilia B
patients [139]. A second theory ties anaphylactic
reactions to excessive immune complex formation
resulting from a large infused load of exogenous FIX
protein with each treatment. The standard dose of
FIX is 40–80 IU kg)1, which exposes patients to
200–400 lg of exogenous protein. In contrast,
standard dosing for FVIII deficient patients is 25–
50 IU kg)1, which exposes them to just 2.5–5.0 lg
of factor [138,139]. Finally, molecular genetic char-
acterization of FIX inhibitors reported to the registry
showed that FIX inhibitor patients whose haemo-
philia B resulted from complete gene deletions had a
26% risk for anaphylactic reactions [140]. It has
been postulated that since FIX gene deletions are
sometimes extremely large [141], codeletion of
immune response modifier genes could trigger aller-
gic responses in otherwise susceptible patients [139].
To date, the immunology of both FIX inhibitor
development and its associated allergic phenomena
have been difficult to study in a definitive way.
However, FIX genotyping may identify children at
greatest risk for inhibitor development and anaphy-
laxis [138] and should be performed for every patient
with severe haemophilia B at the time of initial
presentation [58].
Allergic-type reactions in patients with inhibitors
preclude the use of FIX-containing products unless
patients are thoroughly desensitized. Consideration
may be given to desensitization to improve the
management of bleeding episodes, but the response is
inconsistent. Moreover, even after patients become
desensitized, most continue to have recurrent allergic
reactions to FIX that require premedication with
antihistamines and steroids [138].
The success of ITI in eradicating FIX inhibitors is
low, particularly in patients with the allergic pheno-
type [22]. Among 16 haemophilia B subjects in the
NAITR who completed ITI, five had a successful
outcome using FIX therapeutic dosing regimens that
ranged from 43 to 200 IU kg)1 daily [22]. This
group included one patient with an inhibitor-associ-
ated allergic phenotype and three whose inhibitors
were not allergic in nature. Adverse events were
reported during 11 of 17 (65%) ITI courses admin-
istered to individuals with FIX inhibitors, a fre-
quency 10 times higher than that for persons with
FVIII inhibitors. The 11 courses were complicated by
14 reactions to treatment. Allergic reactions accoun-
ted for 11 of 14 adverse events and occurred in the
10 registry subjects already known to exhibit allergic
reactions to FIX replacement therapy subsequent to
the development of inhibitors. Of those 11, three
were severe reactions and the cause of premature ITI
cessation. Overall, allergic reactions represented the
major reason for failure in at least four of 11
unsuccessful courses of ITI in haemophilia B.
The International Society on Thrombosis and
Haemostasis (ISTH) Registry on FIX Inhibitors data
reveal that ITI was successful in only five of the 34
patients (15%) in whom it was attempted, and two
of those patients had low-responding inhibitors
[137]. Moreover, 13 of the 34 patients (38%)
developed nephrotic syndrome during ITI [137]. An
association between allergic reactions to FIX in
inhibitor patients undergoing ITI and the develop-
ment of nephrotic syndrome was also noted in the
NAITR cohort [22]. In all, three of 10 such subjects
developed nephrotic syndrome while undergoing
immune tolerance, accounting for three of 14 reported
Fig. 2. Mild haemophilia A: recommended management
algorithm.
14 D. M. DIMICHELE et al.
 2007 The Authors
Haemophilia (2007), 13 (Suppl. 1), 1–22 Journal compilation  2007 Blackwell Publishing Ltd
adverse events. This complication is primarily asso-
ciated with a history of allergic phenotype inhibitors
[142,143] and has been observed with all FIX
products [143]. Although there have been reports
of return to normal renal function with cessation of
ITI alone, corticosteroid therapy has been required
by some patients with variable success [142]. Neph-
rotic syndrome has not been reported in patients
undergoing ITI for FVIII inhibitors, which may
reflect the lower amounts of FVIII in plasma,
compared with FIX (approximately 1:50 on a
mg mL)1 basis) [137,142].
An alternative immunosuppressive strategy for the
treatment of FIX inhibitors described by German
researchers has been successful in a single patient
[144]. A 5-year-old boy with severe haemophilia B
underwent ITI using a regimen that included myco-
phenolate-mofetil, dexamethasone and intravenous
immunoglobulin together with high-dose FIX. After
8 weeks, his inhibitor had disappeared, FIX recovery
and half-life had normalized, and he did not develop
nephrotic syndrome.
Desensitization may be needed prior to ITI initi-
ation, but this process does not transform risk from
poor to good, nor does it preclude the development
of nephrotic syndrome. The decision to attempt ITI
for FIX inhibitors must be very carefully weighed
against the relatively high-risk of adverse reactions
and the relatively low likelihood of success, partic-
ularly in those patients whose inhibitor is associated
with an allergic phenotype [58]. Consequently, if
immune tolerance is initiated, particularly in that
subset of patients, physicians are urged to proceed
with great caution and to perform routine urinalyses
during ITI to detect proteinuria and early nephrotic
syndrome [138].
Consensus recommendations for ITI in patients with
haemophilia B (Fig. 3):
1 There can be no recommendations for ITI in hae-
mophilia B.
2 If ITI is initiated, proceed with caution and per-
form routine urinalyses during treatment to
evaluate for nephrotic syndrome (level IV).
3 Parameters for ITI success and failure established
by consensus for FVIII inhibitors cannot be ap-
plied to define success in haemophilia B.
Research priorities
Immune tolerance is a costly process that is unsuc-
cessful in approximately 20–40% of patients with
severe haemophilia A [136] and a far greater
percentage of those with mild haemophilia A and
haemophilia B [137]. Moreover, many patients are
not candidates for ITI because of the presence of
long-standing inhibitors, the expense of treatment,
unfavourable risk-benefit ratios, or patient/family
issues. Thus, inhibitory antibodies are persistent in a
substantial number of individuals, severely jeopard-
izing their health and the quality of their lives. To
design optimal and cost-effective therapies that
prevent and treat inhibitors requires deepened under-
standing of the immunology of inhibitor formation
and of the mechanisms that promote tolerance. The
following high-priority research areas were identified
by the International Consensus Panel:
Immunologic aspects of inhibitor development
Antibody formation against FVIII is a CD4-positive
(CD4+) T cell-dependent process that requires T-cell
interaction with antigen-presenting cells together
with T-cell and B-cell interaction [145]. The failure
to activate regulatory CD4+ cells may play a crucial
role in the development of FVIII inhibitors and is an
area that requires ongoing investigation [146].
Immunology of FVIII tolerance
Tolerance is an active process that can be both
induced and antigen-specific [147]. Although the
basic mechanisms of the immune response to FVIII in
the setting of factor replacement therapy are being
elucidated, further study is needed to clarify the
relevance of these mechanisms in the context of
successful ITI and, ultimately, gene therapy [146].
Fig. 3. Haemophilia B: recommended management algorithm.
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Haemophilia and inflammatory cytokine mediator
genotypes
Haemophilia genotype and the genotype for host
immune responses influence the risk of inhibitor
development [29,36]. Whether these genotypes also
influence the response to ITI is unclear and is a focus
of ongoing investigations.
Role of FVIII dose in ITI success
This parameter is under intensive study and, it is
hoped, will be clarified through the I-ITI study.
Role of FVIII purity in ITI success
In vitro experiments showed that VWF prevents the
interaction of FVIII with endocytic receptors that
degrade and eliminate FVIII from the circulation
[148]. In these studies, increasing the molar ratio of
VWF to FVIII above the physiologic ratio of 50:1
decreased the endocytosis of FVIII by dendritic cells.
Increasing plasma concentrations of VWF may
decrease the amount of FVIII presented to T
lymphocytes, thereby reducing T-cell activation.
Findings from the RESIST trial and an ongoing
German observational study by Kreuz and colleagues
may determine if VWF/FVIII products improve ITI
success rates or if VWF is simply a surrogate marker
for other beneficial components present in pdFVIII.
Other questions related to the role of VWF/FVIII
interaction that may be explored:
1 The role of endogenous VWF levels on ITI success
2 Correlation of ABO blood grouping to ITI success
3 Differences in immunologic processing of VWF-
bound FVIII and unbound (free) FVIII.
4 Differences in efficacy between high-purity
pdFVIII and VWF-containing pdFVIII.
Role of infection, catheter infection and catheter
thrombosis on ITI success
Both infection and thrombosis are common compli-
cations in patients with CVADs [97,99,101,102].
Their true impact on ITI success may be clarified in
the I-ITI study.
Alternative strategies for treating bleeding episodes and
inducing tolerance
Preclinical studies suggest that innovative strategies,
such as bypassing inhibitors with human/porcine
FVIII hybrid concentrates, blocking or neutralizing
inhibitors using peptide decoys or anti-idiotypic
antibodies, administering FVIII to the nasal or gut
mucosa, and gene transfer technology, may enhance
the management of bleeding events in inhibitor
patients or improve the likelihood of successful
tolerization. Clinical trials are needed to determine
if the results obtained in the laboratory and in
animals translate to success in patients.
Immunologic definition of ITI success/failure
Despite the ubiquitous use of pharmacokinetic
parameters to define ITI success or failure, these
parameters vary considerably among patients, and
no firm evidence supports the defining values [57].
Furthermore, these parameters may be insufficient,
given that approximately 4.3% of patients relapse
after successful ITI, according to registry data
[55], an observation also noted in the ongoing IITI
study. An immunologic definition of success may
provide more useful information on when to start
or stop ITI; how to tailor immune tolerance to the
individual patient; how to maintain tolerance after
ITI; and, in general, how to better manage
haemophilia A and B.
Immunology of inhibitor development and tolerance
in mild haemophilia A
It is unclear whether patients with mild haemophilia
A who undergo successful ITI achieve true toler-
ance, or if they remain at risk for anamnesis upon
reexposure to FVIII. An immunologic definition may
be essential to determine the success or failure of
immune tolerance in this subset of inhibitor patients.
The findings from the French-Belgium registry will be
of critical importance in identifying useful inhibitor
prevention and management strategies.
Alternative strategies for ITI in haemophilia B patients
with inhibitors associated with anaphylaxis
ITI is unlikely to be successful in haemophilia B
patients with the anaphylactoid phenotype
[138,149]. Improving upon these success rates
requires an enhanced understanding of the immuno-
logy of haemophilia B-related anaphylaxis.
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